Alzheimer Disease (AD) is a neurodegenerative disease characterized by two
neuropathological hallmarks: extracellular deposition of amyloid plaques and intracellular …

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the
pathogenesis of Alzheimer's disease (AD) is substantial. Yet, only a few anti-amyloid agents …

The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and
Alzheimer disease (AD) is arguably the clearest instance of crosstalk between …

Abstract Development of disease‐modifying treatments for Alzheimer's disease (AD) has
been challenging, with no drugs approved to date. The failures of several amyloid‐targeted …

Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

Amyloid-β (Aβ) deposits are a relatively late consequence of Aβ aggregation in Alzheimer's
disease. When pathogenic Aβ seeds begin to form, propagate and spread is not known, nor …

The complexity of Alzheimer's disease (AD) complicates the search for effective treatments.
While the key roles of pathologically modified proteins has occupied a central role in …

Two of the key functions of arteries in the brain are (1) the well‐recognized supply of blood
via the vascular lumen and (2) the emerging role for the arterial walls as routes for the …

Dementia is one of the main causes of disability among elderly people. It is a progressive
neurodegenerative disease that affects elderly people's ability to perform daily living …

Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent
effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) …